Target- |
MechanismImmunostimulants |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.AU |
First Approval Date24 Sep 2002 |
Target- |
MechanismImmunostimulants |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.DE |
First Approval Date12 Oct 1999 |
Target- |
MechanismImmunostimulants |
|
|
|
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc. |
First Approval Date24 Feb 2009 |
Phase III, multi-center, randomized, active-controlled, open-label, three-arm, study in 690 infants who will receive a 3-dose primary series at 6, 10 and 14 weeks of age, of either 3-dose SHAN6™ or SHAN6™ – SHAN 5® + bOPV – SHAN6™ or SHAN 5® + bOPV – SHAN 5® + bOPV – SHAN 5® + bOPV + IPV, and a booster dose of either SHAN6™ or SHAN 5® + bOPV at 18 months of age
100 Clinical Results associated with Sanofi Pasteur Europe
0 Patents (Medical) associated with Sanofi Pasteur Europe
100 Deals associated with Sanofi Pasteur Europe
100 Translational Medicine associated with Sanofi Pasteur Europe